Learn the current clinical progress and unmet needs in hemophilia A treatment.
Review of the current and emerging factors including extended half-life factors, immunogenicity, and how to use pharmacokinetics to individualize therapy.
Learn about emicizumab and its impact on monitoring assays and surgical management in hemophilia A.
Learn the rationale and efficacy and safety data for emerging extended half-life factor replacement and nonfactor replacement strategies for hemophilia A, including mimetics, rebalancers, and gene therapy.
Explore practical issues in hemophilia A, including managing breakthrough bleeds, surgery, immune tolerance induction, and previously untreated patients.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.